Back to browse

EXP001992

Paper

Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Treatment of Triple-Negative Breast Cancer (2021)

Peptide

Octaarginine (R8)

Sequence: RRRRRRRR

RNA

siRNA

All experiment fields

Experiment Id EXP001992
Paper Cell-Penetrating Peptide-Modified Graphene Oxide Nanoparticles Loaded with Rictor siRNA for the Trea
Peptide Octaarginine (R8)
Delivery Success Class no
In Vivo Flag no
Uptake Confirmed yes
Label Confidence high
In Vitro Functional Effect yes
Endosomal Escape Evidence
Peptide Concentration CPP solution added to GO-PEI-PEG at final 1 mM during synthesis (then washed); transfection doses reported as siRNA 0–150 nM in assays.
Rna Concentration Typically 50–150 nM siRNA in vitro (MTT uses 0, 50, 100, 150 nM).
Mixing Ratio Optimum mass ratio siRNA : GO-PEI-PEG-CPP = 1 : 0.5 (gel retardation screen; GO:PEI ratio 1:60–1:100 gives complete binding at 1:0.5).
Formulation Format GO-PEI-PEG-CPP/siRNA nanocomplex (graphene oxide + PEI + PEG + CPP)
Formulation Components Graphene oxide (GO) + polyethyleneimine (PEI, MW 800) + polyethylene glycol (PEG, MW 2000) + CPP R8, loaded with Rictor siRNA-2 (or Cy5-labeled siRNA for uptake).
Size Nm 231.60
Zeta Mv 16.10
Model Scope in_vitro
Model Type in vitro
Cell Lines Or Primary Cells MDA-MB-231 (triple-negative breast cancer) cells
Animal Model
Administration Route
Output Type In vitro functional RNA effect: Rictor knockdown (qPCR/WB) + phenotypic assays (MTT, colony formation, apoptosis)
Output Value Rictor siRNA-2 reduces Rictor expression; GO-PEI-PEG-CPP/siRNA enhances uptake vs non-CPP and reduces viability / colonies and increases apoptosis vs controls.
Output Units
Output Notes Uptake shown by confocal microscopy and flow cytometry with Cy5-siRNA; functional effects include reduced Rictor and downstream p-Akt/p-p70s6k plus increased Annexin V/PI apoptosis.
Toxicity Notes Body-weight effects addressed in vivo; in vitro cytotoxicity assessed by MTT/colony/apoptosis.
Curation Notes